Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trials

被引：0

作者：

Foley, Peter ^{[1
,2
]}

Zhang, Jianzhong ^{[3
]}

Imafuku, Shinichi ^{[4
]}

Ding, Yangfeng ^{[5
]}

Okubo, Yukari ^{[6
]}

Li, Hui ^{[7
]}

Tada, Yayoi ^{[8
]}

Li, Linfeng ^{[9
]}

Ohtsuki, Mamitaro ^{[10
]}

Pan, Weili ^{[11
]}

Lu, Yan ^{[12
]}

Hao, Cheng ^{[13
]}

Xian, Jiang ^{[14
]}

Ho, Ji-Chen ^{[15
]}

Guo, Shuping ^{[16
]}

Seo, Seong Jun ^{[17
]}

Napoli, Andrew ^{[18
]}

Chatterjee, Arkendu ^{[18
]}

Kisa, Renata M. ^{[18
]}

Banerjee, Subhashis ^{[18
]}

Morita, Akimichi ^{[19
]}

机构：

[1] Univ Melbourne, St Vincents Hosp Melbourne, Prob Med Res, Melbourne, Vic, Australia

[2] Skin Hlth Inst, Melbourne, Vic, Australia

[3] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[4] Fukuoka Univ Hosp, Fukuoka, Japan

[5] Shanghai Skin Dis Hosp, Shanghai, Peoples R China

[6] Tokyo Med Univ, Tokyo, Japan

[7] Chongqing Med Univ, Affiliated Hosp 1, Shanghai, Peoples R China

[8] Teikyo Univ, Sch Med, Tokyo, Japan

[9] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[10] Jichi Med Univ, Shimotsuke, Tochigi, Japan

[11] Peoples Hosp Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China

[12] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China

[13] Zhejiang Univ, Sir Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China

[14] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[15] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[16] Shanxi Med Univ, Hosp 1, Jinzhong, Shanxi, Peoples R China

[17] Chung Ang Univ Hosp, Seoul, South Korea

[18] Bristol Myers Squibb, New York, NY USA

[19] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Japan

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：28 / 29

页数：2

共 50 条

[31] Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
Blauvelt, Andrew
Rich, Phoebe
Sofen, Howard
Strober, Bruce
Merola, Joseph F.
Lebwohl, Mark
Morita, Akimichi
Szepietowski, Jacek C.
Lambert, Jo
Hippeli, Lauren
Colston, Elizabeth
Balagula, Eugene
Banerjee, Subhashis
Thaci, Diamant
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 775 - 782
[32] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials (vol 14, pg 2235, 2024)
Armstrong, April W.
Augustin, Matthias
Beaumont, Jennifer L.
Pham, Tan P.
Hudgens, Stacie
Gordon, Kenneth B.
Zhuo, Joe
Becker, Brandon
Zhong, Yichen
Kisa, Renata M.
Banerjee, Subhashis
Papp, Kim A.
DERMATOLOGY AND THERAPY, 2025, : 1037 - 1044
[33] DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Korman, N. J.
Passeron, T.
Gordon, K. B.
Okubo, Y.
Bagel, J.
Sofen, H.
Warren, R. B.
Bhatia, N.
Spelman, L.
Winthrop, K.
Hippeli, L.
Kisa, R. M.
Banerjee, S.
Thaci, D.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1774 - 1775
[34] Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Psoriasis: Absolute PASI Outcomes in a Phase 3 Trial
Okubo, Yukari
Imafuku, Shinichi
Tada, Yayoi
Ohtsuki, Mamitaro
Shao, Yanqiu
Colston, Elizabeth
Napoli, Andrew
Hippeli, Lauren
Banerjee, Subhashis
Morita, Akimichi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
[35] Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials
Lebwohl, Mark
Warren, Richard B.
Kircik, Leon
Colston, Elizabeth
Hippeli, Lauren
Napoli, Andrew
Kisa, Renata M.
Banerjee, Subhashis
Menter, Alan
Thaci, Diamant
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[36] Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
Gottlieb, Alice B.
Armstrong, April W.
Merola, Joseph
Napoli, Andrew
Nowak, Miroslawa
Banerjee, Subhashis
Lehman, Thomas
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2782 - 2785
[37] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial
Imafuku, Shinichi
Okubo, Yukari
Tada, Yayoi
Ohtsuki, Mamitaro
Colston, Elizabeth
Napoli, Andrew
Shao, Yanqiu
Banerjee, Subhashis
Morita, Akimichi
JOURNAL OF DERMATOLOGY, 2024, 51 (03): : 365 - 379
[38] EFFICACY OF THE ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)
Gottlieb, Alice B.
Armstrong, April W.
Merola, Joseph F.
Napoli, Andrew
Nowak, Miroslawa
Banerjee, Subhashis
Lehman, Thomas
Mease, Philip J.
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[39] Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
Armstrong, April W.
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Morita, Akimichi
Paul, Carle
Papp, Kim A.
Colombo, Matthew J.
Scotto, Julie
Vaile, John
Zhuo, Joe
Vritzali, Eleni
Berger, Victoria
Schroeder, Georgene
Banerjee, Subhashis
Thaci, Diamant
Strober, Bruce
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
[40] Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial
Zhang, Jianzhong
Ding, Yangfeng
Wang, Ping
Li, Linfeng
Pan, Weili
Lu, Yan
Cheng, Hao
Jiang, Xian
Ho, Ji-Chen
Guo, Shuping
Liu, Leona
Chatterjee, Arkendu
Kisa, Renata M.
Banerjee, Subhashis
BRITISH JOURNAL OF DERMATOLOGY, 2025, 192 (03) : 402 - 409

← 1 2 3 4 5 →